Artikel
Novel candidate for molecular therapeutic targets in gliomas
Suche in Medline nach
Autoren
Veröffentlicht: | 4. Juni 2012 |
---|
Gliederung
Text
Objective: In the present study, we screened novel molecular targets for glioma therapy, and verified their validity for clinical use.
Methods: To identify novel therapeutic targets for glioma, we performed two different ways of screening, those are 1: gene expression analysis using cDNA microarray in combination with the result of expression database in internet (NCBI EST database), 2: serological screening (modified SEREX). After screening, we focused on several molecules and performed expression analysis and functional analysis using siRNA technique.
Results: From the result of cDNA microarray, we have identified four candidate genes for glioma-specific genes; (uPARAP, LPAR2, GM2A, CDKN1A). From the result of serological screening we have isolated 6 genes; (SPAG6, LRIG2, Protamine1, KIF23, SYCP1, SMC4). Among the genes screened, we focused on uPARAP and KIF23. Downregulation of uPARAP significantly suppressed glioma cell migration and invasion in vitro. Downregulation of KIF23 expression significantly suppressed glioma cell proliferation in vitro and also in vivo.
Conclusions: Our study identified several candidate molecular target genes for novel glioma therapy. Although downregulation of one gene seems not to be sufficient for glioma treatment, the results could contribute to recognize glioma biology.